These inhibitors bind to both GDP-bound and GTP-bound KRAS(G12D), efficiently disrupt KRAS–CRAF interaction, but do not bind to wide type and G12C mutant KRAS. Our studies showed that they disrupted MAPK signaling, reduced tumor volume, and synergized with an anti-PD1 antibody in mouse ...
KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia. Cell. Physiol. Biochem.: Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 33, 78-87.Zhao S, Zhang Y, Sha K, Tang Q, Yang X, Yu C et al (2014) KRAS (G12D) Cooperates with...
Cancer-associated RAS mutations occur frequently in acute myeloid leukemia (AML), suggesting a functional role for Ras in leukemogenesis.We successfully established a mouse model of human leukemia by transplanting bone marrow cells co-transfected with the K-ras (G12D) mutation and AML1/ETO fusion...
产品名称 KRAS-G12D/SOS1 ASSAY KIT - 500 TESTS 用途范围 500Tests 是否进口 是 Sample size 16 uL 最终测定体积 20 uL 套件组件 Lyophilized standard, frozen detection antibodies, buffers &protocol. Time to result 3h at RT Species Human only 可售卖地 北京;天津;河北;山西;内蒙古;辽宁;...
Using a microsatellite stable (MSS) colorectal cancer (CRC) cell line (Colo741) having mutated BRAF and KRASWT, we also aimed to investigate the KRAS-BRAF interaction. Gene expression profiles for control KRASWT, KRASG12V and KRASG12D transfected cells were obtained after cell clone selection ...
Pasca di Magliano (University of Michigan) for providing us with the doxycycline-inducible KrasG12D mouse. We thank A. Dannhorn (AstraZeneca) for establishment of the MSI sample preparation method and A. Dannhorn and N. Strittmatter (AstraZeneca) for DESI optimization. We thank the members ...
MOUSE PANCREATIC CANCER CELLS FROM KRASG12D/P53−/− TRANSGENIC MICE OVEREXPRESS HEAT SHOCK PROTEIN 70 (HSP70), AND ITS INHIBITION BY TRIPTOLIDE DECREA... MOUSE PANCREATIC CANCER CELLS FROM KRASG12D/P53−/− TRANSGENIC MICE OVEREXPRESS HEAT SHOCK PROTEIN 70 (HSP70), AND ITS INHIBITION ...
KRAS在多种实体肿瘤中均会发生基因突变,其中胰腺导管腺癌发生突变的几率最高,突变形式包括KRAS-G12D、KRAS-G12C和KRAS-G12V等。而在非小细胞肺癌中,KRAS基因以KRAS-G12C点突变最为常见。当KRAS基因出现G12C点突变后,其本身具备的GTP水解酶活性就会丢失,进而激活RAF-MEK-ERK、PI3K-AKT-mTOR和Ral-GDS等多条...
Wouter W等人分析比较了464例应用不同方案化疗对KRAS突变患者的影响[3],发现紫杉醇联合铂的客观缓解率(ORR)及PFS要优于应用培美曲塞联合铂类的治疗方案,在亚组分析中发现存在G12V突变患者,紫杉醇类药物显著改善了ORR(67%, P <0.01),但未观察到PFS和总生存(OS)的延长;然而存在G12C或G12D突变的患者在所有...
KrasG12D in the metastasis of pancreatic cancer S Rachagani et al 700 P < 0.001 600 500 400 300 200 1043 CD18/HPAF-Scr 70 60 50 40 30 20 10 0 CD18/HPAF-Scr CD18/HPAF-shKras *** CD18/HPAF-shKRas 100 CD18/HPAF-Scr CD18/HPAF-ShKras Group CD18/HPAF-Scr Mouse pancreatic ...